What is known and objective: Some public scepticism exists about generics in terms of whether brand and generic drugs produce identical outcomes. This study explores whether adverse event (AE) reporting patterns are similar between brand and generic drugs, using authorized generics (AGs) as a control for possible generic drug perception biases. Results and discussion: Generics accounted for significant percentages of total U.S.
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Summary
What is known and objective: Some public scepticism exists about generics in terms of whether brand and generic drugs produce identical outcomes. This study explores whether adverse event (AE) reporting patterns are similar between brand and generic drugs, using authorized generics (AGs) as a control for possible generic drug perception biases. Interrupted time series analysis evaluated the impact of generic entry on reporting trends.
Results and discussion: Generics accounted for significant percentages of total U.S.
reports, but AGs accounted for smaller percentages of reports, including for amlodipine (14.26%), losartan (1.48%), metoprolol ER (0.35%) and simvastatin (0.70%).
Whereas the RORs were significantly different for multiple brand vs generic comparisons, the AG vs generic comparisons yielded fewer statistically significant findings. Namely, only the ROR for AG differed from generic for amlodipine with peripheral oedema (P < .01).
What is new and conclusion: Inconsistent reporting patterns were observed more between brand and generic compared with AG and generic. Use of AGs as a control for perception biases against generics is useful, but this approach can be limited by small AG report numbers. Requiring the manufacturer name to be printed on the prescription bottle or packaging could improve the accuracy of assignment for products being reported.
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| WHAT IS KNOWN AND OBJECTIVE
Some public scepticism exists about generic drugs. The U.S. FDA generic drug approval process is very rigorous, and much of the public scepticism is believed to be simply a biased perception of generics because of factors such as lower cost, lack of generic product promotion (and heavy brand promotion) and simply a different look and feel of generics compared with brands. [1] [2] [3] [4] [5] [6] Given these potential public biases against generics, studying generic drug utilization patterns and outcomes in the real world poses methodological challenges. For instance, if an observational study comparing generic tolerability vs brand tolerability was conducted in the real world, it is likely that patients taking generics would likely report more tolerability concerns than patients taking brands just by virtue of this generic bias. This phenomenon has been illustrated in prior studies where patients taking "generic" placebo reported fewer benefits and more adverse events (AEs) than patients taking "brand" placebo for headaches.
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One possible way to overcome this challenge is by studying authorized generic (AG) drugs. AG drugs contain the exact active and inactive ingredients as the branded drugs and are marketed under the brand drug's New Drug Application (NDA), but are sold and distributed with a generic label. 8 The marketing of the AG drugs began early in the 1990s as a strategy for brand name companies to maintain market share, but become a widespread practice in 2003. The therapeutic efficacy and safety profile of the brand drug and AG are identical, but patients perceive the AG to be similar to other generics, which are approved via Abbreviated New Drug Applications (ANDAs). Therefore, it may be feasible to use AG drugs as "control drugs" in post-marking surveillance research.
This study explored whether AE reporting patterns are similar between brand and generic drugs, using AG drugs as a control for 
| Reports identification
We included reports when amlodipine (Norvasc), metoprolol ER (Toprol XL), losartan (Cozaar) and simvastatin (Zocor) were listed as the primary or secondary suspect drugs. We excluded reports when these drugs were listed as interacting or concomitant. We used text string searches for each drug by generic names, brand names and abbreviations. As drug name misspellings are possible among reported events, we used complete name and shorter character strings to identify a subset of reports. Drug names in these reports were then recoded by one reviewer, and a second reviewer verified the accuracy of the recoding.
Reports were classified as brand, AG or generic based on the manufacturer making the report. Manufacturers were identified based on the filer of the NDA for brand, based on manufacturers other than the brand company marketing the drug under the NDA for AGs and based on filers of ANDAs for generics. Although generally this approach works, the manufacture making the report might not be the actual manufacturer of the reported product. For instance, a patient might report the AE of a generic drug to the brand name company out of familiarity or vice versa. Reports made directly to the FDA were excluded as these reports usually do not include manufacturer name. For amlodipine, brand reports and AG reports were from Pfizer. Because the brand and AG were coded from the same manufacturer, we differentiated between the two using verbatim name. If the drug was reported by the brand name (Norvasc), then it was classified to be brand, and if it was reported by the generic name amlodipine, then it was classified to be an AG. For losartan, brand reports were from Merck Sharp Dohme, AG reports were from Sandoz, and generic reports were from all other manufacturers. For metoprolol ER, brand reports were from AstraZeneca, AG reports were from Par Pharmaceuticals, and generic reports were from all other manufacturers. For simvastatin, brand reports were from Merck Sharp Dohme, AG reports were from Dr.
Reddy's Lab, and generic reports were from all other manufacturers.
| Measures
We estimated the total number of overall AE reports and the number of serious AE reports, categorized as death, disability and other serious outcomes. Previously documented AEs were identified based on the most recent product label and drug reference databases (Micromedex, Truven Health Analytics, Ann Arbor, MI, USA and Lexi-Comp, Wolters
Kluwer, Hudson, OH, USA). The events investigated for each product are listed in Table 1 for each drug. These AEs were identified in FAERS reports from the REAC files using the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) noted in the supplemental data. We employed existing categorization approaches to group specific PTs into broader AE terms. We grouped all PTs listed in the Standardized MedDRA Query (SMQ) when the AEs of interest reasonably corresponded with an SMQ. 15 When SMQs were considered to be an inadequate definition of the event of interest, we used a hierarchical search process. 16 We first examined high-level group terms (HLGTs), then highlevel terms (HLTs) and then individual PTs. The broadest of these definitions was selected to define the event of interest.
| Data analysis
Descriptive analyses were performed to summarize the sources of AE reports for each drug. Reporting odds ratios (RORs) with 95% confidence intervals were estimated with disproportionality analyses, which evaluated the likelihood of documented events to be reported with a specific type of product (ie, brand, AG or generic) in comparison with all other drugs in FAERS. In particular, cases were reports of the AE of interest and non-cases were all reports of AEs other than the event of interest.
The ROR estimates the odds of the event of interest in those exposed to each target drug product of interest divided by the odds of the event of interest in those exposed to all other drugs in FAERS. We calculated the ROR for each drug-product type (ie, brand, AG, generic).
Because possible measurement error with our approach to classifying brand vs AG vs generic reports was considered to be non-constant over time, we only analysed the period after the introduction of the generic into the U.S. market (Table 1) . The magnitude and direction of the RORs were compared across drug-product types. Additionally, Breslow-Day tests were used to examine homogeneity of the RORs for AG and generic compared to the brand product, as well as compared with each other. To minimize potential type 1 error, we used a Bonferroni correction to adjust for multiple comparisons with a critical P-value <.01. Interrupted time series with segmented regression was performed to evaluate the impact of generic entry on reporting trends. 17 In a series of linear regression models, the change in the slope and intercept of the number of the worldwide reported AE per quarter was estimated from the pregeneric period to post-generic period for each drug. We used the FDA received date (ie, FDA_DT) to define the corresponding quarter for each report. All statistical analyses were performed using sas version 9.4. This study was determined to be exempt non-human subject research by the Auburn University
Institutional Review Board and the FDA Research in Human Subjects Committee.
| RESULTS
As shown in We examined the impact of AG and generic entry on reporting trends by performing an interrupted time series analysis (Table 2) .
We performed the analysis for all drugs except for metoprolol ER due to the low sample size. Only losartan showed a significant increase in the reporting trend in the post-generic period (P-value = .0001).
Sensitivity analyses were conducted using manufacturer submitted date and event date instead of FDA received date. The losartan results
showed a significant increase in AE reports when using the event date (P-value = .02).
We then compared the RORs across drug types for known AEs on the package label and in drug reference databases (Figure 1 ). We ob- 
| DISCUSSION
Generic drugs reduce healthcare costs, and both payers and providers recommend their use. 18, 19 Given that the market share of generic drugs is more than 80%, 20, 21 ongoing attention needs to be paid to monitor their safety and efficacy and promote public confidence in their use. The FAERS database is a tool used broadly for safety signal detection, but it has not been widely used to assess differences in AEs reporting between brand and generic drugs. Whereas we recognize that the FAERS is not designed to consistently capture specific brand vs generic drug-product signals, it could play a role as a generic drug safety surveillance tool. Further, employing the use of AG drugs as a "control" to account for generic drug perception bias is a novel approach to generic drug safety surveillance.
We explored reports of known AEs of amlodipine, losartan, metoprolol ER and simvastatin. We compared the RORs of brand vs generic, brand vs AG and AG vs generic to explore potential differences in the reporting rates. Our results showed that no significant differences were found for many AEs when comparing AGs and generics. Assuming the AG represents the brand product in terms of safety and effectiveness but is perceived as a generic, this would suggest that the reporting differences between brand and generic are at least in part related to perception bias. For example, the generic losartan ROR for acute renal failure was significantly higher than the corresponding brand ROR (P-value <.01), yet no significant difference between AG and generic RORs was found (P = .37). This finding was consistent across most drugs; however, there were a few cases that trended towards a difference, and one case where we found a statistically significant difference between AG and generic. Namely, the ROR for AG was significantly higher than generic for amlodipine with peripheral oedema. Our results demonstrate that the public perception bias against generics is found in AE reporting.
A number of different factors could have influenced our findings. to primary suspects and valid serious primary suspects, the misclassification was minimized, but at the cost of sample size. Restricting to just US primary suspect reports seemed to be a reasonable compromise to maintaining sample size while minimizing misclassification. This is illustrated in Figure 2 , whereby a relatively high number of reports are assigned to generic even before the generic was available in the market (ie, these are brand reports misclassified as generic) when we looked at total US reports. When we restricted to US primary suspect reports, the proportion of reports that are obviously misclassified is significantly reduced.
Also, the small number of reports for AGs limits the usefulness of our approach to controlling for generic drug perception bias. It is likely that patients and providers are more aware of brand manufacturer name than the generic manufacturer, so they report to the brand name manufacturer out of familiarity. Promoting the importance of reporting to the correct manufacturer may help increase the proportion of generic and AG reports. Also, printing the manufacturer name on prescription drug bottles or packaging could increase the generic and AG reporting rate accuracy.
FDA Adverse Event Reporting System is prone to several limitations due to its nature as a spontaneous reporting system. Reported
AEs for a specific drug do not necessarily mean that the drug was causally responsible for that event. Also, we do not have an actual denominator that represents the drug utilization in the USA or information regarding a patient's past medical history. Similar to other spontaneous reporting systems, FAERS is prone to reporting biases.
Reporting rates may be stimulated due to factors such as media coverage, FDA warnings, or advertisements from law firms. However, we do not know of any major issues that might have impacted reporting with these drugs during the study period. It is important to note that FAERS is suited for hypothesis generation and further study of any possible signals detected should employ other data sources and study designs, such as the FDA Sentinel Initiative.
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| WHAT IS NEW AND CONCLUSION
Although brand vs generic comparisons showed higher AE report rates for generics, AG vs generic comparisons showed few significant differences in reporting rates, suggesting biases exist against generics when reporting in FAERS. The small number of cumulative AG reports over time could have influenced these findings. The reliability of using AGs for post-marketing surveillance could be improved through policy changes that require both the manufacturer and NDA or ANDA numbers on prescription bottles to facilitate accurate reporting by consumers and physicians to either the FDA or manufacturers. Our innovative approach of using AGs to account for perception biases against generics can be useful when AG use and reporting are relatively common and should be further investigated for post-marketing surveillance.
